金河生物：具体经营情况届时请关注公司披露的相关公告

Core Viewpoint - The company reported a decline in profits for the third quarter due to routine maintenance in the chemical medicine workshop, the seasonal downturn in industry consumption, increased production capacity from the launch of the sixth phase project, and promotional discounts offered by the company [2] Group 1 - The main reasons for the profit decline include routine maintenance, seasonal consumption downturn, increased production capacity, and promotional discounts [2] - The company raised the price of gold mycin in domestic and other export markets at the end of November, which may positively impact the fourth quarter's performance [2] - Investors are advised to monitor the company's announcements for specific operational updates [2]